KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Shares Outstanding (Diluted Average) (2018 - 2025)

Historic Shares Outstanding (Diluted Average) for NovoCure (NVCR) over the last 8 years, with Q3 2025 value amounting to $111.9 million.

  • NovoCure's Shares Outstanding (Diluted Average) rose 338.16% to $111.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.9 million, marking a year-over-year increase of 338.16%. This contributed to the annual value of $107.8 million for FY2024, which is 135.65% up from last year.
  • Per NovoCure's latest filing, its Shares Outstanding (Diluted Average) stood at $111.9 million for Q3 2025, which was up 338.16% from $111.6 million recorded in Q2 2025.
  • In the past 5 years, NovoCure's Shares Outstanding (Diluted Average) registered a high of $111.9 million during Q3 2025, and its lowest value of $102.6 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $106.3 million (2023), whereas its average is $106.4 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first plummeted by 648.38% in 2021, then soared by 359.51% in 2025.
  • NovoCure's Shares Outstanding (Diluted Average) (Quarter) stood at $103.4 million in 2021, then rose by 1.19% to $104.7 million in 2022, then grew by 1.65% to $106.4 million in 2023, then rose by 1.36% to $107.8 million in 2024, then grew by 3.78% to $111.9 million in 2025.
  • Its last three reported values are $111.9 million in Q3 2025, $111.6 million for Q2 2025, and $110.3 million during Q1 2025.